Balancing Acts: An Analysis of Food and Drug Administration Letters about Direct-to-Consumer Advertising Violations

Journal of Public Policy and Marketing

Volumn 22, Issue 2, 2003, Pages 159-169

  Sheehan, Kim Bartel ^a  

^a UNIVERSITY OF OREGON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0346283222     PISSN: 07439156     EISSN: 15477207     Source Type: Journal    
DOI: 10.1509/jppm.22.2.159.17645     Document Type: Review

References (38)

1. Advertising Age (1998), "FDA Warned," 69 (32), 10.
2. Aiken, Kathryn J. (2000) "Direct-to-Consumer Advertising of Prescription Drugs: Current Issues," paper presented at the Advertising Club of New York, New York (October 8).
3. Baylor-Henry, Minnie V. and Janet L. Rose (2003), "Communicating with FDA's Advertising Groups," in How to Work with the FDA, 2d ed., Wayne L. Pines, ed. Hagerstown, MD: Food and Drug Law Institute, 35-50.
4. Belkin, Lisa (2001), "Primetime Pushers," Mother Jones, 18 (March-April), 31-37.
5. Bunis, Dena (2000), "Direct to You," (accessed April 4, 2003), [available at http://www.salon.com/health/feature/2000/02/23/drug_ads].
6. Calfee, John (1997), Fear of Persuasion: A New Perspective on Advertising and Regulation. London: Agora.
7. _ (2002), "Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs," Journal of Public Policy & Marketing, 21 (Fall), 174-92.
8. Charatan, Fred (2000), "US Prescription Drug Sales Boosted by Advertising," BMJ: British Medical Journal, 321 (7264), 783.
9. DTC Perspectives (2002), "Interview with Dr. Nancy M. Ostrove, " (accessed April 17, 2002), [available at http://www.DTCperspectives.com].
10. Elliott, Victoria Stagg (2003), "FDA Chief Pledges Changes to Direct-to-Consumer Advertising Guidelines," (accessed May 14, 2003), [available at http://www.ama-assn.org/sci-pubs/amnews/pick_03/hlsd0428.htm].
11. FDA (1995), Direct-to-Consumer Promotion. Silver Springs, MD: FDA.
12. _ (1997a), "Letter to Schering," (accessed July 23, 2003), [available at http://www.fda.gov/cder/warn/mar97/claritins.pdf].
13. _ (1997b), "Letter to Searle," (accessed July 23, 2003), [available at http://www.fda.gov/cder/warn/nov97/n20552_coverahs.pdf].
14. _ (1998a), "Letter to Pharmacia," (accessed July 23, 2003), [available at http://www.fda.gov/cder/warn/mar98/6421.pdf].
15. _ (1998b), "Letter to Novartis," (accessed July 23, 2003), [available at http://www.fda.gov/cder/warn/jan99/lescol.pdf].
16. _ (2001a), "Letter to Astra," (accessed July 23, 2003), [available at http://www.fda.gov/cder/warn/2001/10205.pdf].
17. _ (2001b), "Letter to Glaxo," (accessed July 23, 2003), [available at http://www.fda.gov/cder/warn/2001/dd10171.pdf].
18. _ (2003a), "FDA's Mission," (accessed May 15, 2003), [available at http://www.FDA.gov/opacom/morechoices/mission.html].
19. _ (2003b), "Global Summit 2003," (accessed May 15, 2003), [available at http://www.FDA.gov/cder/ddmac/globalsummit2003.index.htm].
20. FTC (2003), "Information for Business," (accessed May 20, 2003), [available at http://www.ftc.gov/bcp/conline/pubs/buspubs/ad-faqs.htm].
21. Goetzl, David, Abbey Klaassen, Ira Teinowitz, and Lisa Sanders (2001), "Dose of Reality," Advertising Age, 72 (30), 1-2.
22. Hall, S. (2001), "Claritin and Schering-Plough: Prescription for Profit," The New York Times, (accessed), [available at http://www.nytimes.com/2001/03/11/magazine/11CLARITIM.html].
23. Henney, Jane E. (2000), "Challenges in Regulating Direct-to-Consumer Advertising," msJAMA, 284 (6), 2242.
24. McClellan, Mark (2003), "Speech before FDLI," (accessed May 15, 2003), [available at http://www.FDA.gov/oc/speeches/2003/fdli0401.html].
25. McInturff, Bill (2001), "While Critics May Fret, Public Likes DTC Ads," Advertising Age, 72 (March 26), 24.
26. National Institute for Healthcare Management Foundation (2001), Prescription Drugs and Mass Media Advertising. Washington, DC: National Institute for Healthcare Management Foundation.
27. Nayyar, Seema (1992), "Green Light for Drug Ads," Adweek, 29 (24), 9.
28. Nordenberg, Tamar (1998), "Direct to You: TV Drug Ads That Make Sense," (accessed February 20, 2003), [available at http://www.FDA.gov/FDAc/features/1998/198_ads.html].
29. Perrault, William D., Jr., and Lawrence E. Leigh (1989), "Reliability of Nominal Data Based on Qualitative Judgments," Journal of Marketing Research, 26 (May), 135-48.
30. Peterson, Melody (2002), "TV Ads Spur a Rise in Prescription Drug Sales," The New York Times, (March 8), B4.
31. Pharmaceutical Research and Manufacturers of America (2000), "Backgrounder and Facts: Direct to Consumer Advertising," (accessed February 11, 2002), [available at http://www.phrma.org/publications/backgrounders/other/DTC.phtml].
32. Roth, Martin S. (1996), "Patterns in Direct-to-Consumer Prescription Drug Print Advertising and Their Public Policy Implications," Journal of Public Policy & Marketing, 15 (Spring), 63-75.
33. Schommer, John, William Doucette, and Bella Mehta (1998), "Rote Learning After Exposure to a Direct-to-Consumer Television Advertisement for a Prescription Drug," Clinical Therapeutics, 20(3), 617-31.
34. Shaw, Michael (2001), "The DTC Dilemma," Pharmaceutical Executive, (accessed February 20, 2003), [available at http://www.HealthcareMedia.com].
35. Sibley, Charlotte E. (2000), "DTC Advertising Studies," research report, Coalition for Healthcare Communication, (April 10).
36. Tanouye, Elyse (2000), "US Develops Expensive Habit with Drug Sector Growth Spurt," The Wall Street Journal Interactive Edition, (January 19), [available at http://www.msnbc.com/news/215163.asp].
37. U.S. GAO (2002), FDA Oversight of Direct-to-Consumer Advertising Has Limitations. Washington, DC: U.S. GAO.
38. Woods, Bob (2001), "Additional Side Effects," (accessed April 10, 2003), [available at http://www.promomagazine.com/ar/marketing_additional_side_effeets/].